Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7255376 | 0.94 | HTR1A (0.39) | HTR1AADRA1AADRA1DADRA1BTP53 | |
| SCHEMBL6191934 | 0.94 | MEN1 (0.43) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL7250226 | 0.93 | HTR1A (0.44) | HTR1AADRA1AADRA1DADRA1BTP53 | |
| SCHEMBL7054236 | 0.91 | AVPR1A (0.41) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL6192783 | 0.90 | HTR1A (0.48) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL6191391 | 0.88 | ADRA1D (0.45) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL6211824 | 0.88 | DRD4 (0.49) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL6192684 | 0.86 | TSHR (0.47) | HTR1AADRA1AADRA1DADRA1BDRD2 | |
| SCHEMBL6195130 | 0.86 | POLB (0.44) | HTR1AADRA1AADRA1DADRA1BTP53 | |
| SCHEMBL6194537 | 0.86 | OPRM1 (0.49) | HTR1AADRA1AADRA1DADRA1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | claimed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | HTR1A 1/4885ADRA1A 36/4885ADRA1D 17/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | HTR1A 1/4885ADRA1A 27/4885ADRA1D 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.